Diversis Capital, LLC, a Los Angeles-based private equity firm focused on acquiring and growing small- and middle-market companies, today announced that it has acquired the majority of the assets of Caligor Rx, Inc. Based in Secaucus, New Jersey with an additional facility in Dartford, UK, Caligor provides services that enable pharmaceutical and biotechnology companies to maximize the value of their clinical supply chain investments. Financial terms of the transaction were not disclosed.
From its roots as a pharmacy started in 1919, Caligor has established itself as a leader in sourcing and distributing comparator drugs for clinical trials worldwide. Complementing its comparator business, Caligor provides regulatory expertise and strategic services for setting up Global Access Programs (GAP). These programs supply investigational medicines to individual patients, and groups of patients, who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives. Caligor’s leadership team has implemented and managed these programs in more than 70 countries.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.